Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Pipeline Review, H1 2018

Publisher Name :
Date: 12-Jun-2018
No. of pages: 59

Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Pipeline Review, H1 2018

Summary

According to the recently published report 'Calcitonin Gene Related Peptide Type 1 Receptor - Pipeline Review, H1 2018'; Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) pipeline Target constitutes close to 9 molecules.

Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Calcitonin receptor-like (CALCRL) also known as the calcitonin receptor-like receptor (CRLR) is a G protein-coupled receptor. The association of CALCRL with different RAMP proteins produces different receptors which with RAMP1 acts as a receptor for calcitonin-gene-related peptide, with RAMP2 acts as a receptor for adrenomedullin-1and with RAMP3 act as a receptor for adrenomedullin-2. It plays an important role in treatment of migraine.

The report 'Calcitonin Gene Related Peptide Type 1 Receptor - Pipeline Review, H1 2018' outlays comprehensive information on the Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III and Preclinical stages are 1, 3 and 5 respectively. Report covers products from therapy areas Central Nervous System, Metabolic Disorders and Undisclosed which include indications Migraine, Dental Pain, Diabetic Neuropathy, Inflammatory Pain, Nerve Injury, Neuropathic Pain, Post-Operative Pain and Unspecified.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL)

- The report reviews Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) targeted therapeutics and enlists all their major and minor projects

- The report assesses Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Pipeline Review, H1 2018

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Overview
Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Companies Involved in Therapeutics Development
Allergan Plc
Amgen Inc
Biohaven Pharmaceutical Holding Company Ltd
Fortress Biotech Inc
Heptares Therapeutics Ltd
Merck & Co Inc
Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Drug Profiles
A-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
atogepant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BHV-3500 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CGRP - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
erenumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HTL-0022562 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MK-8825 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rimegepant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ubrogepant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Dormant Products
Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Discontinued Products
Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Product Development Milestones
Featured News & Press Releases
Jun 01, 2018: Novartis receives positive CHMP opinion for Aimovig (erenumab) for the prevention of migraine
May 18, 2018: Novartis and Amgen announce FDA approval of Aimovig(TM) (erenumab), a novel treatment developed specifically for migraine prevention
Apr 27, 2018: Allergan Announces Second Positive Phase 3 Clinical Trial for Ubrogepant - an Oral CGRP Receptor Antagonist for the Acute Treatment of Migraine
Apr 22, 2018: Biohaven Announces Robust Clinical Data with Single Dose Rimegepant That Defines Acute and Durable Benefits to Patients: The First Oral CGRP Receptor Antagonist to Deliver Positive Data on Pain Freedom and Most Bothersome Symptom in Two Pivotal Phase 3 Trials in Acute Treatment of Migraine
Apr 19, 2018: Biohaven Pharmaceuticals Announces Additional Phase 3 Rimegepant Data to be Released at Investor Event Held Concurrently with the 2018 American Academy of Neurology Meeting in Los Angeles
Apr 17, 2018: Amgen Presents First-Of-Its-Kind Data At AAN Annual Meeting Reinforcing Robust And Consistent Efficacy Of Aimovig (erenumab) For Migraine Patients With Multiple Treatment Failures
Mar 26, 2018: Biohaven Announces Successful Achievement of Both Co-Primary Regulatory Endpoints in Two Pivotal Phase 3 Trials of Rimegepant an Oral CGRP Receptor Antagonist for the Acute Treatment of Migraine
Mar 06, 2018: Biohaven Enrolls First Patient In Phase 3 Clinical Trial To Evaluate Rimegepant Zydis ODT In The Acute Treatment Of Migraine
Mar 01, 2018: Biohaven Announces Positive Results From Bioequivalence Study With Sublingual Rimegepant Zydis Orally Dissolving Tablet
Feb 06, 2018: Allergan Announces Positive Top Line Phase 3 Results for Ubrogepant - an Oral CGRP Receptor Antagonist for the Acute Treatment of Migraine
Jan 22, 2018: Novartis reports erenumab met all primary and secondary endpoints in unique Phase IIIb study in episodic migraine patients who have failed multiple prior preventive treatments
Nov 29, 2017: Aimovig (erenumab) Phase 3 STRIVE Data Published In The New England Journal Of Medicine Demonstrate Significant, Sustained Efficacy In Migraine Prevention
Nov 27, 2017: Biohaven Completes Enrollment In Second Pivotal Phase 3 Clinical Trial Of Oral CGRP-Receptor Antagonist Rimegepant
Nov 20, 2017: Biohaven Receives Agreement From FDA on Initial Pediatric Study Plan for Rimegepant, a Second Generation Oral CGRP-Receptor Antagonist for the Acute Treatment of Migraine
Nov 16, 2017: Biohaven Completes Enrollment In The First Of Two Pivotal Phase 3 Clinical Trials Of Rimegepant, A Second Generation Oral CGRP-Receptor Antagonist, For The Acute Treatment Of Migraine
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indication, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Allergan Plc, H1 2018
Pipeline by Amgen Inc, H1 2018
Pipeline by Biohaven Pharmaceutical Holding Company Ltd, H1 2018
Pipeline by Fortress Biotech Inc, H1 2018
Pipeline by Heptares Therapeutics Ltd, H1 2018
Pipeline by Merck & Co Inc, H1 2018
Dormant Projects, H1 2018
Discontinued Products, H1 2018

List of Figures
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
  • Global Vegetable Capsules Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 22-Jun-2018        Price: US 3480 Onwards        Pages: 129
    Vegetarian capsules are all-natural, GMO free, plant-based shell, free from animal derivatives, gluten, and modified sugars. Nowadays, Vegetarian capsules can be divided into several kinds such as Plant Polysaccharides (Pullulan), Starches, and HPMC (Hydroxyl Propyl Methyl Celluloses). Vegetarian capsules possess the benefits of suited for Halal or Kosher certification; Pure, clear and elegant appearance with no taste or odor; Ideal for improving the bioavailability of oil soluble ingredients; E......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Vegetable Capsules Market 2018, Forecast to 2023
    Published: 22-Jun-2018        Price: US 4880 Onwards        Pages: 131
    Vegetarian capsules are all-natural, GMO free, plant-based shell, free from animal derivatives, gluten, and modified sugars. Nowadays, Vegetarian capsules can be divided into several kinds such as Plant Polysaccharides (Pullulan), Starches, and HPMC (Hydroxyl Propyl Methyl Celluloses). Vegetarian capsules possess the benefits of suited for Halal or Kosher certification; Pure, clear and elegant appearance with no taste or odor; Ideal for improving the bioavailability of oil soluble ingredients; E......
  • Global Sugar Sphere Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 22-Jun-2018        Price: US 3480 Onwards        Pages: 131
    Sugar spheres are a widely used excipient for sustained-release pellet formulations. Sugar spheres (also called neutral pellets, nonpareil seeds, microgranules or sugar beads) are produced, preferably using a layered sugar-coating structure. The result is sugar spheres with sufficient mechanical stability for further processing. Scope of the Report: This report focuses on the Sugar Sphere in global market, especially in North America, Europe and Asia-Pacific, South America,......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Sugar Sphere Market 2018, Forecast to 2023
    Published: 22-Jun-2018        Price: US 4880 Onwards        Pages: 132
    Sugar spheres are a widely used excipient for sustained-release pellet formulations. Sugar spheres (also called neutral pellets, nonpareil seeds, microgranules or sugar beads) are produced, preferably using a layered sugar-coating structure. The result is sugar spheres with sufficient mechanical stability for further processing. Scope of the Report: This report focuses on the Sugar Sphere in global market, especially in North America, Europe and Asia-Pacific, South America,......
  • Global Androstenedione Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 21-Jun-2018        Price: US 3480 Onwards        Pages: 152
    Androstenedione: 4-Androstenedione (androst-4-ene-3,17-dione) - an endogenous weak androgen and estrogen and intermediate to/prohormone of testosterone. Scope of the Report: This report focuses on the Androstenedione in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application. Androstenedione is used to evaluate the function of t......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Androstenedione Market 2018, Forecast to 2023
    Published: 21-Jun-2018        Price: US 4880 Onwards        Pages: 148
    Androstenedione: 4-Androstenedione (androst-4-ene-3,17-dione) - an endogenous weak androgen and estrogen and intermediate to/prohormone of testosterone. Scope of the Report: This report focuses on the Androstenedione in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application. Androstenedione is used to evaluate the function of t......
  • Global Soft Gelatin Capsules Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 21-Jun-2018        Price: US 3480 Onwards        Pages: 152
    Soft Gelatin Capsules are a type of capsules with a solid outer shell and inner surrounding a liquid or semi-solid (inner fill) active ingredient that can be incorporated into the outer shell, the inner fill, or both. Scope of the Report: This report focuses on the Soft Gelatin Capsules in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and ap......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Soft Gelatin Capsules Market 2018, Forecast to 2023
    Published: 21-Jun-2018        Price: US 4880 Onwards        Pages: 150
    Soft Gelatin Capsules are a type of capsules with a solid outer shell and inner surrounding a liquid or semi-solid (inner fill) active ingredient that can be incorporated into the outer shell, the inner fill, or both. Scope of the Report: This report focuses on the Soft Gelatin Capsules in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and ap......
  • Global Keyhole Limpet Hemocyanin (KLH) Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 20-Jun-2018        Price: US 3480 Onwards        Pages: 129
    KLH, which can be used as an active pharmaceutical ingredient ("API"), is a very large, high molecular weight, oxygen-carrying glycoprotein made of millions of atoms. There are two KLH subunit forms, KLH1 and KLH2, each composed of seven or eight functional units, with each functional unit having an oxygen binding site of two copper atoms. Keyhole limpet hemocyanin is an extremely large, heterogeneous glycosylated protein consisting of subunits with a molecular weight of 350,000 and 390,000 in a......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs